In related news, CURR Pharma - CURE Pharmac
Post# of 30027
(Total Views: 542)
Posted On: 07/15/2020 11:41:47 AM
In related news,
CURR Pharma -
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel
OXNARD, Calif. — July 15, 2020 — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film (OTF) showed improved bioavailability of cannabidiol in healthy subjects, compared with 25mg soft gels....
https://www.curepharmaceutical.com/press-rele...-soft-gel/
There are a few things that stand out.
Dr. Lauren Chung is on both a BOD at CURR and
TODOS (a direct connection to Gerald)
CURR's PR is on the improved CBD bioavailability of an oral "film".
AMBS & Hempori have deals with EMOR.
EMOR has it's own oral delivery system.
Emerald Organic Products, Inc. Announces Exclusive Licensing Agreement With PetVivo Holdings Inc.
August 05, 2019 09:55 ET | Source: Emerald Organic Products Inc.
New York, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that it has formally entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC
ETV) (“PetVivo”).
The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth's inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
The fully dissolving wafer-like invention sticks strongly and comfortably the roof of the mouth, cheeks, or gums. This delivery method provides both a rapid release and greater bioavailability when compared to ingestion. Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”).
“The potential introduction of this technology to our line of products can change the entire dynamics and approach to both our vitamin and nutraceutical markets, especially for our flagship PURA CBD products” said Emerald Organic Products, Inc. CEO, Ian Parker.....
https://www.globenewswire.com/news-release/20...s-Inc.html
Interesting to see this is an thatbis showing promise and now with CBD.
Both CBD and Eltoprazine can be absorbed and easily cross the Blood Brain Barrier.
With studies showing a improved results in this type of delivery system, it could help move EMOR, AMBS & Hempori forward.
For patients that don't want to or are unable to swallow pills this is creating a new option/ delivery system for them to get their medications.
CURR Pharma -
CURE Pharmaceutical CBD Oral Thin Film Pharmacokinetic Study Shows Improved Bioavailability Compared to CBD Soft Gel
OXNARD, Calif. — July 15, 2020 — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that its 25mg cannabidiol (CBD) oral thin film (OTF) showed improved bioavailability of cannabidiol in healthy subjects, compared with 25mg soft gels....
https://www.curepharmaceutical.com/press-rele...-soft-gel/
There are a few things that stand out.
Dr. Lauren Chung is on both a BOD at CURR and
TODOS (a direct connection to Gerald)
CURR's PR is on the improved CBD bioavailability of an oral "film".
AMBS & Hempori have deals with EMOR.
EMOR has it's own oral delivery system.
Emerald Organic Products, Inc. Announces Exclusive Licensing Agreement With PetVivo Holdings Inc.
August 05, 2019 09:55 ET | Source: Emerald Organic Products Inc.
New York, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Emerald Organic Products, Inc. (OTC:EMOR) (“Emerald” or the “Company”) is pleased to announce that it has formally entered into an exclusive licensing agreement for the use of OraPatch™, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”) from PetVivo Holdings, Inc. (OTC
ETV) (“PetVivo”). The patented oral adhesion technology, OraPatch™, is a slowly degradable protein wafer-disc that attaches to and assimilates with the mouth's inner lining. PetVivo is the holder of patents for this unique and cutting-edge method for nutraceutical and supplement delivery.
The fully dissolving wafer-like invention sticks strongly and comfortably the roof of the mouth, cheeks, or gums. This delivery method provides both a rapid release and greater bioavailability when compared to ingestion. Furthermore, the OraPatch product only uses materials deemed to be Generally Recognized as Safe (“GRAS”) by the United States Food and Drug Administration (the “FDA”).
“The potential introduction of this technology to our line of products can change the entire dynamics and approach to both our vitamin and nutraceutical markets, especially for our flagship PURA CBD products” said Emerald Organic Products, Inc. CEO, Ian Parker.....
https://www.globenewswire.com/news-release/20...s-Inc.html
Interesting to see this is an thatbis showing promise and now with CBD.
Both CBD and Eltoprazine can be absorbed and easily cross the Blood Brain Barrier.
With studies showing a improved results in this type of delivery system, it could help move EMOR, AMBS & Hempori forward.
For patients that don't want to or are unable to swallow pills this is creating a new option/ delivery system for them to get their medications.
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼